Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 vs Active Surveillance in LS-SCLC
NCT06526624Phase 3Not yet recruiting
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Sep 2024
- Primary completion
- Nov 2027
- Modality
- Antibody-Drug Conjugates (ADCs)
01
Overview
Phase 3, randomised, open-label trial of risvutatug rezetecan in small cell lung cancer (SCLC) (2 arms), sponsored by Hansoh Pharmaceutical Group. Primary endpoints: Progression-Free Survival by IRC at 6 years and Overall Survival at 6 years. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
risvutatug rezetecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT06526624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06526624.